{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:37:07Z","timestamp":1790005027951,"version":"4.0.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli Lilly"},{"name":"Galapagos"},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Galapagos"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1093\/rheumatology\/key225","type":"journal-article","created":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T06:02:20Z","timestamp":1530943340000},"page":"i17-i26","source":"Crossref","is-referenced-by-count":155,"title":["Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis"],"prefix":"10.1093","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C","family":"Taylor","sequence":"first","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"key\n\t\t\t\t2019022610403189100_key225-B1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","article-title":"Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges","volume":"11","author":"Smolen","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B3","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","article-title":"A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective","volume":"36","author":"Taylor","year":"2016","journal-title":"Rheumatol Int"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B6","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/cei.12190","article-title":"Inhibition of Janus kinase\/signal transducer and activator of transcription (JAK\/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds","volume":"174","author":"Migita","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B7","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/ard.2005.050385","article-title":"Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment","volume":"65","author":"Walker","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/ard.2005.037929","article-title":"Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique JAK3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis","volume":"65","author":"Walker","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B9","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Internal Med"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B13","article-title":"Remaining pain in DMARD-naive rheumatoid arthritis patients treated with baricitinib and methotrexate [abstract]","volume":"69(Suppl 10)","author":"Lee","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B16","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B18","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B19","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B21","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of JAK inhibitors under development. Just more of the same?","volume":"58","author":"Westhovens","year":"2019","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cbpa.2016.03.006","article-title":"Janus kinase inhibitors for rheumatoid arthritis","volume":"32","author":"Yamaoka","year":"2016","journal-title":"Curr Opin Chem Biol"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B23","doi-asserted-by":"crossref","first-page":"e000262","DOI":"10.1136\/rmdopen-2016-000262","article-title":"Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis","volume":"2","author":"Fleischmann","year":"2016","journal-title":"RMD Open"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B24","first-page":"2120","article-title":"FDA approves tofacitinib for rheumatoid arthritis","volume":"69","author":"Traynor","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B25","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jcph.734","article-title":"Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food","volume":"56","author":"Lamba","year":"2016","journal-title":"J Clin Pharm"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B26","doi-asserted-by":"crossref","first-page":"e000308","DOI":"10.1136\/rmdopen-2016-000308","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial","volume":"2","author":"Strand","year":"2016","journal-title":"RMD Open"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s13075-015-0825-9","article-title":"Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B29","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/rheumatology\/kev442","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis","volume":"55","author":"Strand","year":"2016","journal-title":"Rheumatol"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B30","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/acr.23004","article-title":"Tofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient-reported outcomes from a phase III randomized controlled trial","volume":"69","author":"Strand","year":"2017","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.22453","article-title":"Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial","volume":"67","author":"Strand","year":"2015","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B32","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B33","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/14656566.2017.1359256","article-title":"Efficacy of baricitinib in the treatment of rheumatoid arthritis","volume":"18","author":"Richez","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B34","first-page":"144","article-title":"Baricitinib dose stepdown following disease control in patients with rheumatoid arthritis","volume":"75(Suppl 2)","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B35","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1136\/annrheumdis-2017-211259","article-title":"Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study","volume":"76","author":"Keystone","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B36","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2016-209821","article-title":"Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B37","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","year":"2019","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/rheumatology\/kew329","article-title":"Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies","volume":"56","author":"Schulze-Koops","year":"2017","journal-title":"Rheumatol"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/annrheumdis-2017-eular.1335","article-title":"Effects of baricitinib on haemoglobin and related laboratory parameters in rheumatoid arthritis patients","volume":"76(Suppl 2)","author":"Kay","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B40","doi-asserted-by":"crossref","first-page":"A62","DOI":"10.1136\/annrheumdis-2016-209124.147","article-title":"Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies","volume":"75(Suppl 1)","author":"Emery","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/annrheumdis-2015-eular.3674","article-title":"Relationship between NK cell count and important safety events in rheumatoid arthritis patients treated with tofacitinib","volume":"74(Suppl 2)","author":"van Vollenhoven","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B43","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/art.40036","article-title":"Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase IIb study of patients with active rheumatoid arthritis","volume":"69","author":"Kremer","year":"2017","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B45","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2017-212461","article-title":"Lipid profile and effect of statin treatment in pooled phase 2 and phase 3 baricitinib studies","volume":"77","author":"Taylor","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022610403189100_key225-B47","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","article-title":"Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial","volume":"374","author":"van Vollenhoven","year":"2009","journal-title":"Lancet"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/Supplement_1\/i17\/27984860\/key225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T16:46:02Z","timestamp":1751733962000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/Supplement_1\/i17\/5365417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":47,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2019,2,26]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key225","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,2,1]]}}}